Novel heterogeneous catalysis achieves deracemization in pharmaceuticals, highlighting an innovative solution for compatibility issues.
Cocrystallization-induced deracemization is a powerful route to enantiopure pharmaceuticals, yet is hindered by detrimental interactions between homogeneous catalysts and chiral components. Herein, we report a novel heterogeneous catalysis strategy using metal-organic frameworks (MOFs) to overcome this compatibility challenge. By encapsulating the base catalyst 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) into ZIF-8, we created a ZIF-8@DBU composite catalyst, that effectively isolates the catalyst while preserving its racemization activity. This enabled the efficient deracemization of racemic DMY via cocrystallization, selectively yielding either the (2R,3R)- or (2S,3S)-enantiomer simply by switching the handedness of the coformer, N-benzyl-1-phenylethylamine (NBP). Remarkably, the product yield reached up to 52%, surpassing the 50% theoretical limit of conventional chiral resolution techniques. The strategy proved general, extending successfully to ZIF-67@DBU and ZIF-90@DBU. This work demonstrates the feasibility of using tailored MOF composites to overcome long-standing compatibility barriers in deracemization and opens avenues for their broader application in asymmetric synthesis.
No takes yet. Share an insight, caveat, or question.
Su et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: